undamentalytics Newsletter
Sign in

Seres Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Seres Therapeutics, Inc. had total assets of $138m, total liabilities of $94.0m and shareholders' equity of $44.2m. It held $45.8m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents7455368665116180163128314616
Receivables————29———000
Inventory———————030———
Total current assets20819815593100269304195175394942
Total assets217273190120132343355349359140138102
Accounts payable58765414174421
Deferred revenue (current)——12205———————
Total current liabilities113032424646828699411920
Long-term debt————252524501100——
Total debt200025252551110000
Total liabilities121401291691811682233384031269467
Shareholders' equity20513361−48−4817513211−45144435
Shares outstanding—————————9m10m10m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: KRSA vs MCRBMCRB vs OVIDABSI vs MCRB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Seres Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Seres Therapeutics, Inc.